Pomegranate juice or concentrate,
does it really help with Improvement of erectile function and IIEF in men with mild to moderate erectile dysfunction?
research showsPomegranate juice or concentrate is rated D because the evidence does not establish improvement in erectile function or IIEF in men with mild to moderate erectile dysfunction. The direct human evidence is dominated by one small double-blind crossover trial comparing POM Wonderful pomegranate juice with placebo. Among 53 completers, subjective Global Assessment Questionnaire improvement was 47% versus 32%, but P=0.058 and did not meet the prespecified significance threshold. The validated IIEF erectile-function domain was clearly null at P=0.72. No large independent confirmatory trial was found, and a 2024 network meta-analysis of nutraceuticals found no significant benefit for most regimens over placebo. This is a different clinical axis from corpus item 150, where pomegranate received C for antioxidant and blood-pressure surrogate outcomes. Food use is generally safe, but sugar, calories, product variation, and possible drug interactions must be considered separately.
ads claimClaims that pomegranate boosts nitric oxide like natural sildenafil, that vascular benefits necessarily restore erections, or that IIEF improved convert mechanism, surrogate outcomes, and the direction of a nonsignificant pilot study into clinical efficacy. The validated IIEF result did not differ from placebo, and the GAQ also missed statistical significance.
Useful facts when choosing a product
- Pomegranate juice and concentrates are foods or supplements, not standard approved medicines for erectile dysfunction. Juice content, sugar, polyphenol concentration, and serving size vary substantially among products.
- The key trial used 237 mL daily for four weeks of a specific Wonderful-variety branded juice. Its findings cannot be assumed for other concentrates, powders, or multi-ingredient supplements.
- Typical food amounts are generally well tolerated, but juice and concentrates can be high in sugar and calories. People managing diabetes or weight should check nutrition labels, and gastrointestinal symptoms or allergy can occur.
- Pomegranate inhibits CYP3A4 and CYP2C9 in vitro, but small human studies have not demonstrated a clear clinically important interaction, so real-world risk remains uncertain. People taking warfarin, another narrow-therapeutic-index drug, or multiple prescriptions should discuss concentrated products with a clinician or pharmacist.
What the research actually shows
The randomized double-blind placebo-controlled crossover trial by Forest and colleagues enrolled 61 men and had 53 completers. After two four-week interventions separated by a two-week washout, GAQ and IIEF were assessed; GAQ was nonsignificant at P=0.058 and the IIEF erectile-function domain was nonsignificant at P=0.72. The 2021 systematic review by Leisegang and Finelli likewise recorded no significant placebo-adjusted increase in IIEF-5 for pomegranate. The 2024 network meta-analysis by Barbonetti and colleagues compared 15 nutraceutical trials and 1,000 men; statistically significant benefits versus placebo were confined to selected arginine or carnitine combinations, while most regimens were ineffective. In vitro or animal vascular relaxation and human blood-pressure or antioxidant data do not establish clinical erectile-function benefit.
Why this is classified as D (30)
The grade is not ? because a small direct double-blind crossover trial exists, but its subjective GAQ result was P=0.058 and its validated IIEF result was P=0.72. No large independent replication exists and evidence is concentrated in one branded product, supporting D with 30 points. The C rating for pomegranate blood-pressure and antioxidant surrogates in item 150 concerns a different efficacy axis and was not transferred. Food safety remains separate from efficacy.
Counterpoint. Erectile dysfunction can signal cardiovascular disease, diabetes, medicine effects, hormonal disease, neurologic disease, or psychological distress. Persistent symptoms call for evaluation, lifestyle measures, and evidence-based treatment such as a phosphodiesterase type 5 inhibitor when appropriate; pomegranate juice should not delay care.
Rejudgment record. New verdict — Excluded ? because a directly matching double-blind crossover trial with 53 completers exists, but applied D because subjective GAQ at P=0.058 and validated IIEF at P=0.72 were both nonsignificant, evidence was limited to one branded product with no large independent replication, and the separate C rating for pomegranate blood-pressure and antioxidant surrogates was not transferred
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Subjective improvement of erectile function in mild to moderate erectile dysfunction | D | GAQ improvement was 47% versus 32%, but P=0.058 and was not significant versus placebo. |
| Improvement of IIEF in mild to moderate erectile dysfunction | D | The validated IIEF erectile-function domain was clearly null at P=0.72. |
| Treatment of erectile dysfunction with pomegranate concentrate or supplements | D | A nonsignificant single branded-juice trial cannot be extended to other concentrates, and no independent confirmatory trial exists. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Forest CP et al. 2007 | Randomized double-blind placebo-controlled crossover trial | 53 | POM Wonderful branded-product study; funding details not stated in the PubMed abstract | Four-week GAQ and validated IIEF erectile-function domain | GAQ improvement was 47% with pomegranate versus 32% with placebo, P=0.058, and IIEF did not differ at P=0.72. | Only key direct human trial; null |
| Leisegang K, Finelli R. 2021 | Systematic review of alternative and herbal treatments for erectile dysfunction | 1 | Reported no external funding | Erectile function centered on IIEF outcomes | It summarized no significant placebo-adjusted increase in IIEF-5 in the pomegranate-juice trial. | Review confirming the direct null result |
| Barbonetti A et al. 2024 | Systematic review and network meta-analysis of nutraceutical randomized trials | 1,000 | Not clearly reported in the abstract record | IIEF-5 or IIEF-6 erectile-function score | Most nutraceutical regimens were not statistically superior to placebo apart from selected arginine or carnitine combinations. | Context showing poor replication across nutraceuticals |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-07-21).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-21 · Corrections: none
Cite this verdict
[Chamgap] Pomegranate juice or concentrate x improved erectile function and IIEF in mild to moderate erectile dysfunction — Evidence Grade D·30. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/mens/pomegranate-juice-mild-moderate-erectile-dysfunction-iief/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.